The cleaved PARP expression was reduced during crizotinib treatment due to resistance, but increased in the trametinib alone and more increased in combination treatment (Fig 3B), indicating that the MEK inhibitor combination treatment is effective in EBC-1 CRS cells. The gene discussed is MAP2K7; the disease is congenital rubella syndrome.